The Drug Enforcement Administration has issued a final rule that, effective April 5, will permanently place the synthetic opioid brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever their existence is possible, into schedule I of the Controlled Substances Act.
This rule makes permanent the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I substances on persons who import, export, manufacture, distribute, possess, engage in research on, or conduct instructional activities with this substance, which include the following.
- any person who engages in the above activities with respect to this substance must be registered with the DEA to conduct such activities
- all importation and exportation of this substance must be in compliance with 21 USC 952, 953, 957, and 958 and in accordance with 21 CFR part 1312
- all labels, labeling, and packaging for commercial containers of this substance must comply with the requirements of 21 CFR part 1302
- any activity involving this substance that is not authorized by, or is in violation of, the CSA is unlawful and potentially subject to administrative, civil, and/or criminal sanctions
Copyright © 2023 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.